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Oral form of citicoline, a nootropic and neuroprotective drug in use for almost five
decades, recently was pronounced a food supplement in both USA and EU. The
idea of adding citicoline to topical treatment of primary open angle glaucoma (POAG)
aimed at decreasing intraocular pressure (IOP) appeared as a logical consequence of
accepting neurodegenerative character of this disease. Experimental data, and also few
clinical studies indicate that this substance has potential to counteract some important
pathological mechanisms which seem to contribute to POAG initiation and progression,
such as excitotoxicity and oxidative stress.
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INTRODUCTION
Citicoline is the INN (International Non-proprietary Name) of cytidine-diphosphocholine
(CDP-Choline) marketed in several countries as an injectable nootropic drug since 1970’s. Because
of lack of toxicity and perfect tolerance recently oral citicoline has been authorized as a food
ingredient in both USA and the European Union (for details see Grieb, 2015a). In 2002 two
of us reviewed citicoline pharmacodynamics and pointed to its beneficial effects in glaucoma,
which at that time were thought to be related mainly to stimulation of intracellular synthesis of
phosphatidycholine (Grieb and Rejdak, 2002). Since then many new important findings have been
published concerning both glaucoma and citicoline, which prompted us to review this subject once
more.
GLAUCOMA: CLINICAL LANDSCAPE
The term ‘‘glaucoma’’ or ‘‘glaucomatous optic neuropathy’’ (GON) describes a chronic human
ophthalmic disease, in the course of which the neuroretinal rim of the optic nerve becomes
progressively thinner and the optic nerve cup enlarges (Kwon et al., 2009). Worldwide glaucoma
is the second most frequent eye disease and the leading cause of irreversible blindness. There are
two major types, primary open angle (POAG) in which the iridocorneal angle is open, and angle
closure glaucoma. POAG is usually presented as the most common type which accounts for three
quarters of all glaucomas (see e.g., Kapetanakis et al., 2015).
GON can occur at any level of intraocular pressure (IOP) and, contrary to what had been
thought previously, normal tension glaucoma seems to be quite frequent, may even comprise
about one half of the POAG patients (Heijl, 2011). Moreover, among patients displaying
increased IOP (>21 mmHg, the condition called ocular hypertension) the majority neither have,
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nor will ever develop symptomatic glaucoma. For example, in
an Italian study which comprised 4927 subjects over 40 years of
age, the overall prevalence of ocular hypertension, hypertensive
POAG and normal tension glaucoma was 2.1%, 1.4% and 0.6%,
respectively (Bonomi et al., 2001). In a Japanese study (Kitazawa
et al., 1977) 75 patients with IOP above 21 mmHg were followed
for over 9 years without treatment, and only seven of them (9.3%)
developed glaucoma with visual field loss. Probably the longest
follow-up of untreated ocular hypertension was reported in a
Danish study, in which 41 persons with ocular hypertension and
38 persons with normal IOP were followed. Over 20 years the rate
of glaucoma development reached 34% in initially hypertensive
and 5% in initially normotensive individuals (Lundberg et al.,
1987). Although elevated IOP appears to be the most important
modifiable risk factor of glaucoma, certainly other factors are
involved.
POAG is an indolent disease, developing over many years,
with age being very important but unmodifiable risk factor. Its
natural history can be presented as the ‘‘glaucoma continuum’’
which begins with acceleration of retinal ganglion cells (RGC)
death, then progresses to detectable change in the retinal nerve
fiber layer (RNFL) and narrowing of the visual field, and
ultimately leads to blindness (Weinreb et al., 2004). In a recent
article (Wollstein et al., 2012) RNFL thickness at which visual
field damage becomes detectable has been determined, and
it was concluded that a substantial structural loss (∼17%) is
necessary to cause functional loss detectable with the current
testing methods of standard automated perimetry. The rate of
disease progression is very variable, although the opinion has
been presented that the mean rates of visual field deterioration
depend on disease subtype, being the slowest in normal
tension glaucoma and the fastest in exfoliation glaucoma (Heijl,
2011).
During the major part of the glaucoma continuum the
disease is either undetectable, or asymptomatic, which may be
termed ‘‘preglaucoma’’. It has been argued that screening for
a predisease (i.e., a disease in the asymptomatic phase) would
make sense only if the following three conditions are met:
(1) patients designated as having it are far more likely to develop
symptomatic disease than the rest of the general population;
(2) there is a feasible intervention that effectively reduces the
likelihood of developing full-blown disease; (3) benefits of
intervening on predisease outweigh harms. Currently there is no
screening test for pre-glaucoma which fulfills these requirements
(Viera, 2011). Screening is also not recommended because of
potential harm of overdiagnosis and overtreatment of people
who would never develop noticeable vision problems (Moyer
et al., 2013). A technique which might provide a sensitive
biomarker for retinal ganglion cell function and could be used
to identify patients in whom glaucoma damage is incipient before
visual field changes occur, is pattern electroretinography (PERG),
a test that measures the electrical activity generated by retinal
cells in response to a standardized light stimulus (Bach and
Hoffmann, 2008). Unfortunately PERG is technically demanding
and not suitable for routine ophthalmic diagnostics.
Pharmacological treatment of POAG, which should
be reserved to symptomatic patients, is presently based
exclusively on topically applied drugs that decrease IOP
by decreasing aqueous production, increasing its outflow,
or both. The most popular medications are prostaglandin
analogs (e.g., latanoprost), β-blockers (e.g., timolol), a carbonic
anhydrase inhibitor (dorzolamid) and a selective α2 adrenergic
receptor agonist (brimonidine). However, treatment of POAG
is frequently ineffective. Randomized clinical trials have
demonstrated progression of the disease despite significant IOP
lowering; older age and greater IOP fluctuation increased the
odds of visual field narrowing progression (Nouri-Mahdavi et al.,
2004). In a real life the major problem is poor adherence, its rates
reported as 30–80%. In a recent article (Newman-Casey et al.,
2015) among 11 major reasons of nonadherence to glaucoma
therapy the following were identified as the most important:
decreased self-efficacy, forgetfulness and difficulty with instilling
drops.
An important aspect of glaucoma is that the disease is not
confined to the RGC layer of retina and to the optic nerve, but it
spreads along the entire retino-geniculo-cortical visual pathway,
up to the visual cortex (Yücel and Gupta, 2008; Bogorodzki
et al., 2014). Whereas it is generally believed that the disease
starts at the level of retina from where the degeneration expands
along the optic nerve, the index of global visual field damage
obtained with a Humphrey perimeter (called the mean deviation,
MD, and expressed in dB) may not be exclusively related to
a retinal dysfunction, but may also reflect an impairment at
the supraretinal level, detectable as an additional prolongation
of visual evoked potentials (VEP; Parisi, 2001). It has been
postulated that treatment of glaucoma should not be confined
to the RGC but should also be directed toward glaucomatous
degeneration-susceptible neurons in the brain (Gupta and Yücel,
2007). Of note in this context is that the recent neuroimaging data
suggest that cerebral microinfarcts may be an intracerebral risk
factor for glaucomatous optic nerve atrophy (Schoemann et al.,
2014).
MECHANISMS OF RGC DEATH AND
BIOMARKERS OF GLAUCOMA
The hallmark of glaucoma is the selective death of RGC, neurons
which ‘‘give birth’’ to axons comprising the optic nerve. Retina is
a part of the central nervous system, and some authors suggested
that, at the molecular level, glaucoma is in many respects similar
to chronic central neurodegenerations like e.g., Alzheimer’s
disease (see e.g., Jindal, 2015). Experimental studies on retinal
cultures and animal models such as chronically increased IOP,
RGC axotomy or partial optic nerve crush show that selective
RGC death evoked by elevation of IOP or injury to the optic
nerve may occur for several reasons such as excitotoxicity,
oxidative stress, failure of axonal transport and neurotrophic
factor deprivation, mitochondrial dysfunction, etc. (Almasieh
et al., 2012; Osborne and del Olmo-Aguado, 2013). A popular
model to study mechanisms of glaucomatous RGC loss is DBA/2J
mice which spontaneously develop iris atrophy with pigment
dispersion, and glaucoma (John et al., 1998). Many non-clinical
results are corroborated by data on biochemical biomarkers in
glaucoma patients (see, for example Pinazo-Durán et al., 2013).
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Some mechanisms currently considered of major importance in
glaucomatous RGC death are outlined below.
Excitotoxicity
Glutamate, a leading excitatory neurotransmitter in the brain
and retina, may act as a neurotoxin. In fact, the first
observation of glutamate neurotoxicity concerned toxicity of
sodium glutamate given peripherally toward cells of the inner
layers of retina (Lucas and Newhouse, 1957). The concept of
excitotoxicity as a pivotal pathomechanism of various acute
and chronic neurodegenerative diseases has been worked out
subsequently.
Several in vitro and in vivo studies have shown that retinal
exposure to glutamate or its analog N-methyl-D-aspartate
(NMDA) is toxic to RGC (reviewed in Barkana and Belkin,
2004). Although in some experiments acute intraocular NMDA
application produced only transient and reversible loss of vision
(Sabel et al., 1995), more relevant to human POAG seemed
to be chronic low-dose elevation in vitreal glutamate, which
was toxic to ganglion cells when maintained for 3 months
(Vorwerk et al., 1996). Purified RGC in vitro were found
resistant to NMDA or glutamate-induced cell death (Ullian et al.,
2004). Yet two other subtypes of glutamate ionotropic receptors,
AMPA and kainate receptors, are present inside RGC synapses
(Sethuramanujam and Slaughter, 2015) and may participate
in RGC death, in cooperation with inflammatory mediators
such as matrix metalloproteinase-9 (Zhang et al., 2004) and
tumor necrosis factor alpha (Cueva Vargas et al., 2015). The
finding of a twofold elevated glutamate level in the vitreous
of glaucoma patients and also monkeys in which glaucoma
had been experimentally induced (Dreyer et al., 1996) provided
further argument to support the hypothesis that excitotoxicity is
involved in this disease.
Oxidative and Nitrosative Stress
These terms describe a situation in which tissue generation of
oxidizing free radicals (reactive forms of oxygen and nitrogen)
exceeds the means of inactivating these, which results in
accumulation of dysfunctional, oxidatively damaged proteins,
lipids and nucleic acids. A wealth of data supports the hypothesis
of an important role of oxidative stress in various preclinical
models of glaucoma (reviewed by Tezel, 2006).
In retina and optic nerve oxidative/nitrosative stress may
be evoked by glutamate excitotoxicity, or may occur for other
reasons, such as dysfunction of mitochondria. Signs of decreased
antioxidant defenses and increased levels of pro-oxidants have
also been identified in the aqueous humor, ocular tissues and
blood of glaucoma patients. For example, Sorkhabi et al. (2011)
reported significantly increased levels of a marker of DNA
oxidative damage 8-hydroxy-deoxyguanosine and decreased
total antioxidant status in both aqueous humor and serum of
POAG patients compared to those with cataracts. Gherghel et al.
(2013) reported on low systemic glutathione levels in blood
of patients suffering from primary open angle hypertensive as
well, as normotensive glaucoma, indicating a compromise of the
antioxidant defense systems.
Failure of Axonal Transport and
Neurotrophin Deprivation
RGC axons traverse a large distance; anterograde continuous
delivery of organellae such as mitochondria and also proteins
from RGC somas is required for maintaining their function.
Impairment of both the anterograde and retrograde axonal
transport is considered an important pathogenic feature of
glaucoma (Fahy et al., 2016).
In particular, brain-derived neurotrophic factor (BDNF),
along with neurotrophins −4 and −5 (NT-4/5) is vital
for maintaining RGCs in the retina. Its trophic effects are
primarily mediated through high-affinity plasma membrane
receptor TrkB. BDNF and TrkB are widely expressed in
the RGCs and lamina cribrosa. Activation of TrkB activates
several pro-survival kinases, including Akt and extracellular
signal-regulated kinases 1 and 2 (Erk1/2). BDNF is produced
locally by RGCs and astrocytes in the retina, but it is also
synthesized in the superior colliculus and the lateral geniculate
nucleus, from where it is retrogradely transported through
RGC axons to the retinal ganglion cell bodies (Harvey et al.,
2012).
In two small studies BDNF levels were found significantly
lower in sera (Ghaffariyeh et al., 2011) and tears (Ghaffariyeh
et al., 2009) of patients with POAG, compared to age-
matched controls without any apparent ocular or systemic
diseases. Although lower BDNF level in glaucoma could be
related to extraocular reasons such as, for example, more
sedentary lifestyle of glaucoma patients (exercise may increase
serum and plasma BDNF level (Coelho et al., 2013), these
data correspond to the concept of BDNF insufficiency in
glaucoma.
Mitochondrial Dysfunction and Apoptosis
Proper function of the retina and optic nerve is critically
dependent on mitochondria that supply ATP necessary to
support their function and structure. Primary and secondary
impairments of these organelles have been shown in cell and
animal glaucoma models and in human glaucoma (Lee et al.,
2011).
In experimental models of glaucoma abundant evidence
has been provided that RGC die through apoptosis (Garcia-
Valenzuela et al., 1995; Schuettauf et al., 2004). Apoptosizing
RGC were found in human POAG (Kerrigan et al., 1997),
and also in anterior ischemic optic neuropathy (Levin
and Louhab, 1996). Apoptosis as the primary pathway of
RGC death in glaucoma and involvement of mitochondria-
generated free radicals in this pathology are currently generally
accepted, although details such as involvement of caspases
(Tezel and Yang, 2004) and possible contribution of other
mechanisms such as autophagy (Wang et al., 2015) are
debated.
In summary it may be concluded that, in response to
glaucomatous stimuli, cross talk between proapoptotic signals
(caspase activation and mitochondrial dysfunction) and survival
promoters (neurotrophins) determines the fate of RGCs (Pinazo-
Durán et al., 2013).
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CITICOLINE: A NEUROPROTECTANT
ACTING THROUGH MECHANISMS
RELEVANT TO GLAUCOMA
The concept of neuroprotection is that structure and function of
diseased neurons can be rescued by interfering with mechanisms
of injury and death pathways. Already 20 years ago Schwartz
et al. (1996) pointed out to the accumulating evidence suggestive
of that, regardless of the primary trigger of the retinal and
optic nerve damage in glaucoma, the disease will continue to
progress even when the cause is removed; therefore substances
which are neuroprotective may be useful for the treatment
of this disease. Since then the idea of complementing IOP
lowering in POAG by neuroprotective treatment has been
endorsed by many authors (two recent examples: Chang and
Goldberg, 2012; Song et al., 2015). Neuroprotective agents should
be helpful in preserving visual function through correcting
the imbalance between cellular death and survival signals and
preventing RGC death and optic nerve damage (Sena and
Lindsley, 2013).
Neuroprotective properties of citicoline have been shown in
various experimental paradigms. Some of them were models of
glaucoma, the others modeled brain neurodegenerative diseases
in which citicoline seemed to counteract various pathological
mechanisms believed to be involved also in glaucomatous
RGC loss.
Rescue of RGC in Partial Optic Nerve
Crush
Partial crush injury of the rat optic nerve has been developed
as a model of progressive degeneration of RGCs which
recapitulates much slower degeneration that occurs in
POAG (Schwartz, 2005). After the short initial phase of
immediate death following mechanical axotomy of some
ganglion cells, the situation in the retina and the optic nerve
attains characteristics similar to a chronic disease. Both in
glaucoma and in the partial optic nerve crush model the
selective and delayed RGC death occurs, whereas the other
cellular layers of the retina are spared. Many ganglion neurons,
although their axons are not damaged by an acute insult,
eventually degenerate as a consequence of the degenerative
environment produced by the initial injury. While it is rather
certain that a primary insult initiating neurodegeneration
of RGCs in glaucoma is different from that which initiates
RGCs death after the callibrated partial optic nerve crush,
it has been assumed that in both cases the self-perpetuating
secondary degeneration of RGCs results from a similar
hostile environment generated by dying neural cells, which
consists of mediators of oxidative stress, free radicals, excessive
extracellular glutamate and calcium ions, and other factors.
Therefore partial optic nerve crush is a quick and relatively
simple experimental paradigm frequently used to assess
neuroprotective efficacy of potential anti-glaucoma drugs (Li
et al., 2014).
Given after partial optic nerve crush, citicoline was found
effective in rescuing RGC connected to their brain targets
(Schuettauf et al., 2006). Similar effects were obtained with
lithium (Schuettauf et al., 2006), which has recently been
identified as a potential neuroprotective agent in central
neurodegeneration (Lazzara and Kim, 2015). Neuroprotection
provided by citicoline and lithium were not additive, moreover
both compounds similarly increased retinal expression of
the apoptotic regulating protein Bcl-2, indicating one of the
mechanisms which may be engaged in the neuroprotective effect
of both citicoline and lithium (Schuettauf et al., 2006). A possible
explanation may be that lithium upregulates BDNF (see Lazzara
and Kim, 2015), whereas citicoline may act as a BDNF mimic (see
below).
Counteracting Excitotoxicity
Although in vitro exposure of cultured RGCs to glutamate
or NMDA, or intravitreal injection of these excitotoxins were
frequently employed for testing neuroprotective efficacy of
various compounds, citicoline has not been tested with any
of these experimental paradigms. However, neuroprotective
effects of citicoline in the adult rat retina were described
after intravitreal injection of kainic acid (KA). Han et al.
(2005) evaluated effects of citicoline on KA-induced changes
in morphometric features of cells and expression of neuronal
and endothelial isoforms of nitric oxide synthase (NOS). In the
second article thickness of various retinal layers were measured
and immunochemical methods were used to visualize the
expression of choline acetyltransferase and tyrosine hydroxylase
(Park et al., 2005). Both types of analysis revealed significant
attenuation of KA-induced damage in retinas from citicoline-
treated animals. An important finding was that intravitreal KA
resulted in increased expression of NOS isoforms, and citicoline
decreased this effect, apparently counteracting nitrosative stress.
In the third report (Park et al., 2006) citicoline was found to
decrease ERK1/2 kinase activation caused by KA.
Anti-Apoptotic Effects and Mimicking
Neurotrophic Factors
Using murine retinal explants Oshitari et al. (2002) have shown
that citicoline can rescue damaged RGCs through an anti-
apoptotic effect and also can support neurite regeneration
of damaged RGCs. In the later report from the same
laboratory (Oshitari et al., 2010) effects of neurotrophic
factors (BDNF, NT-4) or citicoline on neuronal apoptosis and
neurite regeneration in cultured rat retinas exposed to high
glucose (HG) are described. The study showed that BDNF,
NT-4, and to some extent also citicoline reduced the retinal
neuronal apoptosis induced by HG and increased the number
of regenerating neurites. These effects were correlated with
the reduction of the expression of active forms of caspases-
9 and -3. (It is worth to mention that citicoline prevented
brain neuronal caspase-3 activation also in other in vivo
models of neurodegenerative diseases such as rat models
of perinatal brain asphyxia (Fiedorowicz et al., 2008) and
adult brain ischemia (Krupinski et al., 2002; Takasaki et al.,
2011)). Recently it has been confirmed that in rat primary
retinal cultures exposed to toxic levels of glutamate or glucose
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citicoline counteracts neuronal cell damage by decreasing
proapoptotic effects and counteracting synapse loss (Matteucci
et al., 2014).
Retarding Senescence of Brain
Mitochondria
During aging various impairments in mitochondria from
different rat brain areas occur. Intraperitoneal treatment of aged
rats with citicoline at a dose of 20 mg/kg body weight per day
for 1 month caused reversal of some of these age-dependent
changes (Villa et al., 1993). These effects were attributed to
increased availability of cytidilic nucleotides required for the
synthesis of membrane phospholipids phosphatidylserine and
phosphatidylethanolamine and/or to the improvement of brain
energy metabolism. Interestingly, the treatment was effective in
18 month old, but not in 24 month old animals (Villa et al., 2012),
suggesting that citicoline can retard but will not reverse advanced
mitochondrial aging.
Support for the hypothetical positive influence of citicoline
on aging brain mitochondria comes also from a human study
in which 31-phosphorous magnetic resonance spectroscopy
has been used to characterize the effects of this compound
on high-energy phosphate metabolites and constituents of
membrane synthesis in the cortical frontal lobe of middle aged
human volunteers. Significant increases in phosphocreatine,
ATP, the ratio of phosphocreatine to inorganic phosphate,
and changes in membrane phospholipids were observed after
6 weeks of citicoline treatment, suggestive of that citicoline
improves bioenergetics and phospholipid membrane turnover
in a brain region critical for cognition and memory. Citicoline
supplementation may therefore help to mitigate cognitive
declines associated with aging by increasing energy reserves
and utilization, as well as increasing the amount of essential
phospholipid membrane components needed to synthesize
and maintain cell membranes (Silveri et al., 2008). We may
take it for granted that mitochondria are involved in these
improvements.
Effects on Non-Glutamatergic
Neurotransmitter Systems
In the previous review on citicoline and glaucoma (Grieb
and Rejdak, 2002) we indicated data showing that, along with
neuroprotective properties, citicoline injections increased the
levels and enhanced the rate of synthesis of acetylcholine,
dopamine, noradrenaline and serotonin in some brain areas. To
find out whether similar increases occur in retina, we treated
rabbits with 50 mg/kg citicoline intraperitoneally for a week;
following this treatment, significantly increased retinal dopamine
were noted. We concluded that, considering its key role in visual
information processing, elevation of the retinal dopamine may
be responsible, at least partially, for the improvement of visual
function following citicoline treatment of patients with glaucoma
(Rejdak et al., 2002).
It shall be also mentioned that citicoline is an intracellular
donor of choline which mimics electrophysiological and
pharmacological effects of acetylcholine at the alpha7 nicotinic
acetylcholine receptors (α7 nAChR; Alkondon et al., 1997). For
this reason combining citicoline with galantamine, a positive
allosteric modulator of these receptors, has been proposed as a
new approach to schizophrenia treatment (Deutsch et al., 2013).
Recently a new synthetic α7 nAChR agonist has been shown
to prevent loss of RGC in a rat model of glaucoma evoked by
increased IOP (Iwamoto et al., 2014). It is, therefore, possible
that one of the mechanisms by which citicoline rescues RGC in
glaucoma may involve α7 nAChR.
Effects on Demyelination and
Remyelination
Recently beneficial effects of citicoline have been
demonstrated in experimental murine models of autoimmune
encephalomyelitis (EAE) and cuprizone-induced demyelination
(Skripuletz et al., 2015). Qualitatively similar effects of this
compound had been reported previously in rat EAE models,
although only in the abstract form (see Grieb, 2015b).
EAE is a model of multiple sclerosis (MS), which is a
prototypical demyelinating disease. Of note is that patients
suffering from active MS, particularly early in the disease
course, exhibit accelerated thinning of the ganglion cell/inner
plexiform layer in the retina (assessed by the optical coherence
tomography; Ratchford et al., 2013). These findings are
suggestive of retinal changes in MS reflecting global CNS
processes. Effects of citicoline in MS patients have not
been evaluated yet, but such trial is certainly indicated.
Counteracting demyelination and promoting remyelination may
also be relevant in glaucoma; some clinical neuroimaging
data on POAG patients brains present signs of demyelination
(Michelson et al., 2013) which may precede ultimate axonal
degeneration.
CITICOLINE FOR GLAUCOMA: CLINICAL
EVIDENCE
The first report on treatment of POAG patients with
intramuscular citicoline injections was published more than
a quarter of century ago (Pecori Giraldi et al., 1989). The
follow-up of this initial study (Virno et al., 2000) showed an
excellent outcome of the therapy continued for 10 years: only
2 of 11 patients treated with repeated courses of intramuscular
citicoline injections (1 gram daily for subsequent 15 days,
repeated every 6 months), but 5 of 12 patients who did not
receive citicoline injections encountered decreased fraction of
the visual field by at least 500 mm2, as assessed by the Video
Screen Perimetry (Figure 1).
Ten years after the aforementioned first report, results of
a double-blind, placebo-controlled study were published in
which electrophysiological methods (PERG and VEP) were
used to assess function of retinal and supraretinal parts of
the visual pathway. This study showed significant in both
electrophysiological indices of the function of visual pathway
following a course of intramuscular injections of citicoline (Parisi
et al., 1999). Since the improvements were transient, treatment
courses had to be repeated every few months. Long-term
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FIGURE 1 | Survival curves for visual field worsening of primary open angle glaucoma (POAG) patients treated with intraocular pressure
(IOP)-decreasing topical therapy with or without addition of citicoline given intramuscularly. (Reproduced with permission from John Wiley & Sons, Inc.,
Virno et al., 2000).
beneficial effects of repeated courses of citicoline injections in
POAG patients were later confirmed by the electrophysiological
study with follow-up of 8 years (Parisi, 2005).
Because injections are not a preferred treatment for
ophthalmic patients suffering from a chronic disease, in a small
pilot study we tested effects of two biweekly courses of citicoline
given orally in a dose of 1 gram per day, separated by a
2 week break, on VEPs in POAG patients (Rejdak et al., 2003).
Although the study group was small (21 eyes in 11 patients),
highly significant shortening of VEP100 latency, and less marked
but also significant increase in VEP amplitude were found.
Later the effects of citicoline given by intramuscular injections
(1 gram daily) or orally (1.6 gram daily) were compared in the
larger Italian study (Parisi et al., 2008), and the two treatment
modalities were found equivalent. Two months of intramuscular
or oral citicoline doses repeated daily resulted in improvements
in both PERG and VEP; although the positive effects almost
vanished after the next 4 months during which no citicoline was
taken, resumption of the treatment produced even somewhat
larger improvements (Figure 2). The authors concluded that
treatment with citicoline is, indeed, neuroprotective, as it seems
to halt glaucoma progression, but is not curative and must be
periodically repeated to uphold beneficial effects.
Yet another confirmation of long-term beneficial effects
of oral citicoline was provided by the study performed in
three Italian university clinics, in which 41 patients diagnosed
as having progressing POAG despite ‘‘controlled IOP’’ were
treated with oral citicoline solution, dose 500 mg per day
for 4 months, divided by 2-month no-treatment periods
(Ottobelli et al., 2013). The study was not randomized, but
its prospective part was preceded with retrospective assessment
of the pre-treatment rate of progression of the disease as
measured with a Humphrey perimetry. The rate of progression
before treatment initiation was −1.1 dB/year, and during
citicoline treatment it significantly decreased to −0.15 dB/year
(Figure 3).
Recently Parisi et al. (2015) reported on the treatment of
POAG patients with topical application of citicoline in the form
of eye drops. Although the results seemed to be similar to that
of oral citicoline, the idea of topical delivery of citicoline may
not be endorsed. Citicoline is water soluble and will poorly
penetrate cornea. The authors argue that preclinical data show
that citicoline reaches the vitreous provided that high molecular
weight hyaluronic acid and benzalkonium chloride (BAC) are
used as penetration enhancers. BAC, which is currently the most
popular preservative for eye drops, is blamed for inducing ocular
surface changes and several other side effects (Baudouin et al.,
2010). Oral citicoline, usually devoid of any side effects, would be
much more acceptable.
Parenthetically, it is worth to mention that citicoline displays
nootropic properties and its intake is beneficial to patients
with subjective memory disorders or mild or moderate vascular
cognitive impairment (Fioravanti and Yanagi, 2005). We may
thus expect that taking citicoline concomitantly with IOP-
decreasing eye drops might effect in improved adherence to
glaucoma therapy.
CITICOLINE FOR GLAUCOMA IN LIGHT OF
THE EVIDENCE-BASED MEDICINE
In an article discussing analogies between senile dementia
and glaucoma, Jain and Aref (2014) suggested that in both
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FIGURE 2 | Comparison of changes in amplitudes of pattern electroretinograms in POAG patients treated with a topical IOP-decreasing therapy
non-treated open angle glaucoma (NT-OAG), and treated with citicoline intramuscularly open angle glaucoma (TI-OAG) or orally open angle
glaucoma (TO-OAG). ∗p < 0.01, §p > 0.01. (Reproduced with permission from Elsevier, Inc., Parisi et al., 2008).
FIGURE 3 | Change in the rate of progression (RoP) of POAG following addition of oral citicoline to a topical antiglaucoma therapy. B, Baseline.
(Reproduced with permission from Karger Publishers, Ottobelli et al., 2013).
diseases neuroenhancement may be sought by using agents
such as citicoline, currently available as an over the counter
supplement. On the other hand the EFSA Panel on Dietetic
Products, Nutrition and Allergies, delivering an opinion on the
scientific substantiation of a health claim related to the new
food cytidine 5-diphosphocholine and maintenance of normal
vision in elderly subjects since middle age concluded that a
cause and effect relationship has not been established between
the consumption of CDP-choline and maintenance of normal
vision, therefore the aforementioned health claim cannot be
supported (EFSA Panel on Dietetic Products Nutrition and
Allergies (NDA), 2014). We may describe these two contrasting
attitudes as permissive and restrictive, respectively. Somewhat
paradoxically, in the aforementioned examples permissive
attitude concerns the use of citicoline in symptomatic disease
(glaucoma), whereas restrictive attitude concerns its intake by
asymptomatic general population for possible prophylaxis of this
disease.
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Implicit arguments for the restrictive attitude towards oral
citicoline for maintenance of healthy vision were probably
similar to those referred to by the evidence-based medicine
(EBM) in the case of drugs. As the name suggests, EBM is
a code of conduct based on using evidence to make clinical
decisions. A cornerstone of EBM is the hierarchical system
of classifying evidence, known as the ‘‘levels of evidence
pyramid’’, which is directly translatable to the ‘‘grades of
recommendation’’ (Shekelle et al., 1999). The ‘‘gold standard’’
of high-grade evidence is result of prospective, randomized
and blinded, so-called phase III drug trials with properly
designed clinical end points, their metaanalyses and systematic
reviews. Evidence based on non-randomized clinical studies
is considered much less convincing, and recommendations
based on various non-clinical studies (frequently called,
somewhat contemptuously, ‘‘bench research’’) are not trusted
at all.
Undoubtedly, restrictive attitude is praiseworthy toward
drugs which are considerably toxic and very expensive
(these are typical attributes of the so-called ‘‘originator
drugs’’). Indeed, to obtain market authorization for a new
drug, currently it is necessary to demonstrate with a
randomized and blinded study that potential risks related
to treatment are outweighed by therapeutic efficacy. However,
in the case of a food supplement such requirements are
undue. If not excessively ingested, food supplement is
considered totally risk-free, therefore the issue of efficacy
outweighing risks is irrelevant. In the case of citicoline, the
maximum daily dose established by EFSA as totally safe is
500–1000 mg.
Also, it is unrealistic to expect that a cause and effect
relationship will be established between intake of a food
supplement and its prophylactic or therapeutic efficacy. For
example, although yearly world production of vitamin C is
estimated as 110,000 tons (Pollak, 2011), its efficacy in preventing
and treating the common cold is a subject of controversy
for more than 70 years and the issue is still not solved
(Hemilä and Chalker, 2013). In the case of POAG, obtaining
conclusive clinical data on the efficacy of prophylaxis with
a dietary supplement would be even further impeded by
lack of a screening test and the indolent time course of the
disease.
In the Glaucoma Book, a comprehensive review of knowledge
on glaucoma published in 2010 by Springer, citicoline is briefly
mentioned only once, in a chapter written by Zelefsky and
Ritch (2010), devoted to the so-called ‘‘alternative’’ and ‘‘non-
traditional’’ substances usually available over the counter, such
as alpha-lipoic acid, fish oil and omega-3 fatty acids, carnitine
and the like. In the introduction to their chapter the authors
state that in the absence of clinical trials concerning these
natural compounds, it devolves upon the readers to make
the best possible guess as to what might or might not be
effective in glaucoma. As we tried to show, the wealth of
data on neuroprotective properties of citicoline, including some
clinical data, is quite large and convincing. This relatively
old nootropic drug which recently turned out to be a food
supplement seems to be a valuable addition to the conventional
treatment, and also a rational option for prophylaxis of
POAG.
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